{"id":"biochaperone-pdgf-bb","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site reactions"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Hypergranulation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"PDGF-BB is a naturally occurring growth factor that stimulates fibroblast and smooth muscle cell proliferation and migration, promoting new blood vessel formation and extracellular matrix deposition. The BioChaperone technology platform from Adocia uses proprietary formulation approaches to improve the stability, bioavailability, and therapeutic efficacy of PDGF-BB, enabling better tissue regeneration in chronic wounds and other conditions requiring enhanced healing responses.","oneSentence":"BioChaperone PDGF-BB is a formulation of platelet-derived growth factor BB designed to enhance wound healing and tissue repair by promoting angiogenesis and cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:24.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic diabetic foot ulcers"},{"name":"Chronic wounds"}]},"trialDetails":[{"nctId":"NCT02236793","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Assess the Effectiveness of BioChaperone PDGF-BB In the Treatment of Chronic Diabetic Foot Ulcer","status":"COMPLETED","sponsor":"Adocia","startDate":"2014-12","conditions":"Diabetic Foot Ulcer","enrollment":252},{"nctId":"NCT01098357","phase":"PHASE1, PHASE2","title":"Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer","status":"COMPLETED","sponsor":"Virchow Group","startDate":"2010-06","conditions":"Diabetic Foot Ulcers","enrollment":192}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BioChaperone PDGF-BB","genericName":"BioChaperone PDGF-BB","companyName":"Adocia","companyId":"adocia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BioChaperone PDGF-BB is a protein-based drug that acts as an agonist to the platelet-derived growth factor receptor. It is being studied for the treatment of diabetic foot ulcers, with clinical trials comparing its efficacy to Regranex (becaplermin gel) in this indication.","enrichmentLevel":3,"visitCount":2,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}